Back to Sites

St. Mary's CRS

Site Number

30303

Address

St Mary's CRS
St Mary's Clinic
Ingwe Road
Chitungwiza,
Zimbabwe

IMPAACT Members at this Site

Lynda Stranix-Chibanda Clinical/Site Coordinator

Suzen Maonera CRS Coordinator

Tsungai Chipato CRS Leader

Rose A. Kambarami CRS Leader

Teacler Nematadzira CRS Leader

Betty Jowa CRS Staff

Zvavahera Chirenje CTU Principal Investigator

Bola Adedeji DAIDS PO

Tariro Chawana Investigator

Patricia Mandima Investigator

Marshall Munjoma Laboratory Manager/Supervisor

Simbarashe Mujuru Laboratory Technician/Technologist

Bangani Kusakara Medical Officer

Vongai Chanaiwa Pharmacist

Mercy Mutambanengwe Pharmacist of Record

Netsai Mudzonga QA/QC Coordinator

Peter Kanda Quality Assurance

Studies at this Site

P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants

DAIDS Number

10732

Research Area

Tuberculosis

P1084s: Maternal Infant TDF Toxicity Safety

DAIDS Number

10790

Research Area

Complications & Comorbidities

Study Status

Closed to Follow Up

1077BF: PROMISE 1077BF

DAIDS Number

10777

Research Area

Prevention

Study Status

Participants Off Study and Primary Analysis Completed

P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study

DAIDS Number

11954

Research Area

Cure

Study Status

Enrolling

IMPAACT 2009 : Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants

DAIDS Number

30020

Research Area

Prevention

Study Status

Closed to Accrual

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Treatment

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Complications & Comorbidities

Study Status

Open to Accrual

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

38609

Research Area

Treatment

Study Status

Enrolling

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less than 13 Years of Age with and without HIV

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure

Study Status

Enrolling